眼科领域的合作与许可协议（2019-2026）

眼科领域併购的权威基准

我们在眼科领域的合作涵盖了广泛的领域，包括慢性疾病和威胁视力的疾病，我们的合作结构体现了专门的管理方法、标靶治疗和独特的临床开发途径。

本报告对 374 项眼科合作及许可协议进行了全面系统的分析，清晰且基于证据地阐述了整个市场伙伴关係的设计、谈判和执行方式。

充分了解市场标准。

本报告将帮助您全面了解眼科领域的交易结构，并使您能够：

• 自信地对标类似交易
• 对相关合约中的预付款、里程碑付款和特许权使用费结构进行详细分析。
• 设定切合实际的市场参数
• 您可以清楚地了解交易条款如何根据开发阶段、资产类型和合作伙伴情况而有​​所不同。
• 支持实证评估和结构性决策
• 我们将根据实际交易数据进行内部讨论，而不是根据假设。
• 了解主要企业如何处理交易
• 在高度专业化、创新主导的治疗领域中，可视化合作伙伴行为和重复交易结构。
• 全面了解交易结构和执行情况
• 本报告超越了表面的交易数据，提供了对底层合约文件的访问，使您能够详细了解实际合约是如何构建的。

这包括：

• 授予和保留的权利
• 负责开发和商业化
• 财务结构和支付触发机制
• 关键合约条款和保障措施
• 这种程度的透明度在眼科伙伴关係中至关重要，尤其是在需要特殊管理方法和长期治疗方法的领域，以便了解价值、风险和控制是如何分配的。
• 它旨在为实际的业务发展和策略制定提供帮助。

本报告广泛用于以下用途：

• 建置和基准测试实际交易
• 在清晰的市场环境下准备谈判
• 合作机会及交易对象评估
• 支援稳健且引人注目的数据驱动型内部策略
• 本报告内容
• 眼科领域共有 374 项合作与许可协议
• 财务条款，包括预付款、里程碑付款和版税（如有揭露）。
• 可全文搜寻的合约目录（依公司、治疗领域及技术分类）
• 可直接查阅向美国证券交易委员会提交的合约和原始文件。
• 交易趋势分析、关键交易和活跃负责人
• 关于眼科领域交易的可靠、基于证据的参考资料。
• 本报告结合全面的交易覆盖范围和合约层面的洞察，为如何在眼科领域建立、谈判和评估伙伴关係提供可靠的、基于证据的指导。

目录

执行摘要

第一章：引言

第二章：眼科医疗领域併购趋势

• 介绍
• 我们在眼科领域合作多年。
• 眼科领域的合伙（依交易类型划分）
• 眼科领域的合作关係（按行业划分）
• 眼科领域的合作（依发展阶段划分）
• 眼科领域的合作（依技术类型划分）
• 眼科领域的合作（依治疗适应症划分）

第三章 眼科领域合伙企业的财务条件

• 介绍
• 双方将在眼科领域公开合作的财务条款。
• 眼科领域伙伴关係的关键价值
• 眼科相关服务需预付费。
• 眼科相关合约的里程碑付款
• 眼科药物的特许权使用费率

第四章：眼科领域的主要交易和相关人员

• 介绍
• 该公司在眼科领域积极寻求合作伙伴关係
• 眼科领域业务最活跃的公司名单
• 眼科产品超值优惠（依价格排序）

第五章：眼科合约文件清单

• 介绍
• 眼科相关合作协议（如有合约）

第六章：眼科医学交易依治疗标靶分类

• 介绍
• 按眼科治疗目标分類的交易
• 特价优惠列表
• 交易目录 - 眼科相关交易（依公司分类）(AZ)
• 交易目录 - 眼科相关交易（依技术类型分类）
• 交易类型的定义
• 关于这家研究公司
• Current Partnering
• 目前合约
• 理想合作伙伴最新报告的标题

The definitive benchmark for ophthalmics dealmaking

Ophthalmics partnering spans a range of chronic and vision-threatening conditions, with deal structures reflecting specialised delivery methods, targeted therapies, and distinct clinical development pathways.

This report provides a comprehensive and structured analysis of 374 ophthalmics collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how ophthalmics deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a specialised and innovation-driven therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within ophthalmics partnerships, particularly in areas requiring specialised delivery and long-term treatment approaches.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 374 ophthalmics collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for ophthalmics dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how ophthalmics partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in ophthalmics dealmaking

• 2.1. Introduction
• 2.2. Ophthalmics partnering over the years
• 2.3. Ophthalmics partnering by deal type
• 2.4. Ophthalmics partnering by industry sector
• 2.5. Ophthalmics partnering by stage of development
• 2.6. Ophthalmics partnering by technology type
• 2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 - Financial deal terms for ophthalmics partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for ophthalmics partnering
• 3.3. Ophthalmics partnering headline values
• 3.4. Ophthalmics deal upfront payments
• 3.5. Ophthalmics deal milestone payments
• 3.6. Ophthalmics royalty rates

Chapter 4 - Leading ophthalmics deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in ophthalmics partnering
• 4.3. List of most active dealmakers in ophthalmics
• 4.4. Top ophthalmics deals by value

Chapter 5 - Ophthalmics contract document directory

• 5.1. Introduction
• 5.2. Ophthalmics partnering deals where contract document available

Chapter 6 - Ophthalmics dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by ophthalmics therapeutic target
• Deal directory
• Deal directory - Ophthalmics deals by company A-Z
• Deal directory - Ophthalmics deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Ophthalmics partnering since 2019
• Figure 2: Ophthalmics partnering by deal type since 2019
• Figure 3: Ophthalmics partnering by industry sector since 2019
• Figure 4: Ophthalmics partnering by stage of development since 2019
• Figure 5: Ophthalmics partnering by technology type since 2019
• Figure 6: Ophthalmics partnering by indication since 2019
• Figure 7: Ophthalmics deals with a headline value
• Figure 8: Ophthalmics deals with upfront payment values
• Figure 9: Ophthalmics deals with milestone payment
• Figure 10: Ophthalmics deals with royalty rates
• Figure 11: Active ophthalmics dealmaking activity since 2019
• Figure 12: Top ophthalmics deals by value since 2019